We found that SGLT-2 inhibitors can improve the outcome of CV death or HHF both in HF [HR, 0.75(95%CI, 0.65-0.87), P = 0.00001] and T2DM [HR, 0.88(95%CI, 0.78-0.99), P = 0.03] groups. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.